Skip to content
Trial Eligibility
Menu

Lung Cancer Clinical Trials near Nashville, TN

130 studies for Lung Cancer are recruiting at 173 sites within 50 miles of Nashville, Tennessee, according to ClinicalTrials.gov data processed .

Distances are city-level approximations. See all Lung Cancer trials in the US or all trials near Nashville.

Your ZIP is looked up in your browser. We don't receive or store it.

Recruiting now

Lung Cancer studies enrolling near Nashville

Showing the 50 nearest of 130 studies.
  1. A Study to Learn About the Study Medicine Called PF-08046054/SGN-PDL1V Versus Docetaxel in Adult Participants With Previously-Treated Programmed Cell Death Ligand 1 (PD-L1) Positive Non-Small-Cell Lung Cancer (NSCLC)

    NCT07144280

    • Phase 3
    • Ages 18 years and older
    • Sex: All

    Nearest sites: SCRI Oncology Partners (Nashville, TN); Tennessee Oncology, PLLC - Investigational Drug Services (Nashville, TN)

    Distance to nearest recruiting site
    <1 mi (city-level)
    Recruiting sites
    8 sites within 50 mi
  2. Symbiotic-Lung-01 : A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer

    NCT07222566

    • Phase 3
    • Ages 18 years and older
    • Sex: All

    Nearest sites: SCRI Oncology Partners (Nashville, TN); Tennessee Oncology, PLLC - Saint Thomas West (Nashville, TN)

    Distance to nearest recruiting site
    <1 mi (city-level)
    Recruiting sites
    8 sites within 50 mi
  3. Trial of Therapeutic Cancer Vaccine OSE2101 in Patients With Non-Small Cell Lung Cancer and Secondary Resistance to Immune Checkpoint Inhibitor

    NCT06472245

    • Phase 3
    • Ages 18 years and older
    • Sex: All

    Nearest sites: Greco-Hainsworth Tennessee Oncology Centers for Research (GHCR) - Corporate (Nashville, TN); Tennessee Oncology - Nashville - St. Thomas West Clinic (Nashville, TN)

    Distance to nearest recruiting site
    <1 mi (city-level)
    Recruiting sites
    4 sites within 50 mi
  4. A Study of LY4050784 in Participants With Advanced or Metastatic Solid Tumors

    NCT06561685

    • Phase 1
    • Ages 18 years and older
    • Sex: All

    Nearest sites: SCRI Oncology Partners (Nashville, TN); Sarah Cannon Research Institute (Nashville, TN)

    Distance to nearest recruiting site
    <1 mi (city-level)
    Recruiting sites
    3 sites within 50 mi
  5. MOONRAY-01, A Study of LY3962673 in Participants With KRAS G12D-Mutant Solid Tumors

    NCT06586515

    • Phase 1
    • Ages 18 years and older
    • Sex: All

    Nearest sites: Sarah Cannon Research Institute (Nashville, TN); USO - US Oncology Research Network (Nashville, TN)

    Distance to nearest recruiting site
    <1 mi (city-level)
    Recruiting sites
    3 sites within 50 mi
  6. Study of Olomorasib (LY3537982) in Combination With Standard of Care in Participants With Resected or Unresectable KRAS G12C-mutant Non-Small Cell Lung Cancer

    NCT06890598

    • Phase 3
    • Ages 18 years and older
    • Sex: All

    Nearest sites: SCRI Oncology Partners (Nashville, TN); Sarah Cannon Research Institute (Nashville, TN)

    Distance to nearest recruiting site
    <1 mi (city-level)
    Recruiting sites
    3 sites within 50 mi
  7. Molecular Predictors of Cancer in Patients at High Risk of Lung Cancer

    NCT00898313

    • Observational
    • Ages 18 years and older
    • Sex: All

    Nearest sites: Vanderbilt-Ingram Cancer Center (Nashville, TN); Veterans Affairs Medical Center - Nashville (Nashville, TN)

    Distance to nearest recruiting site
    <1 mi (city-level)
    Recruiting sites
    2 sites within 50 mi
  8. A Study of Mevrometostat for Treatment of Relapsed/Refractory SCLC, Castration Resistant Prostate Cancer, and Follicular Lymphoma

    NCT03460977

    • Phase 1
    • Ages 18 years and older
    • Sex: All

    Nearest sites: SCRI Oncology Partners (Nashville, TN); Sarah Cannon Research Institute - Pharmacy (Nashville, TN)

    Distance to nearest recruiting site
    <1 mi (city-level)
    Recruiting sites
    2 sites within 50 mi
  9. Neoadjuvant and Adjuvant Treatment in Resectable Non-small Cell Lung Cancer

    NCT05061550

    • Phase 2
    • Ages 18 to 95 years
    • Sex: All

    Nearest sites: Research Site (Nashville, TN); Research Site (Nashville, TN)

    Distance to nearest recruiting site
    <1 mi (city-level)
    Recruiting sites
    2 sites within 50 mi
  10. Rinatabart Sesutecan (Rina-S, PRO1184, GEN1184) for Advanced Solid Tumors (GCT1184-01/ PRO1184-001)

    NCT05579366

    • Phase 1/2
    • Ages 18 years and older
    • Sex: All

    Nearest sites: Sarah Cannon Research Institute at Tennessee Oncology (Nashville, TN); Tennessee Oncology (Nashville, TN)

    Distance to nearest recruiting site
    <1 mi (city-level)
    Recruiting sites
    2 sites within 50 mi
  11. A Study Evaluating Sotorasib Platinum Doublet Combination Versus Pembrolizumab Platinum Doublet Combination as a Front-Line Therapy in Participants With Stage IV or Advanced Stage IIIB/C Nonsquamous Non-Small Cell Lung Cancers (CodeBreaK 202)

    NCT05920356

    • Phase 3
    • Ages 18 to 100 years
    • Sex: All

    Nearest sites: Sarah Cannon Research Institute (Nashville, TN); United States Oncology Regulatory Affairs Corporate Office (Nashville, TN)

    Distance to nearest recruiting site
    <1 mi (city-level)
    Recruiting sites
    2 sites within 50 mi
  12. A Study of First-Line Olomorasib (LY3537982) and Pembrolizumab With or Without Chemotherapy in Patients With Advanced KRAS G12C-Mutant Non-small Cell Lung Cancer

    NCT06119581

    • Phase 3
    • Ages 18 years and older
    • Sex: All

    Nearest sites: Tennessee Oncology (Nashville, TN); USO - US Oncology Research Network (Nashville, TN)

    Distance to nearest recruiting site
    <1 mi (city-level)
    Recruiting sites
    2 sites within 50 mi
  13. A Study of SGN-CEACAM5C in Adults With Advanced Solid Tumors

    NCT06131840

    • Phase 1
    • Ages 18 years and older
    • Sex: All

    Nearest sites: SCRI Oncology Partners (Nashville, TN); Sarah Cannon Research Institute - Pharmacy (Nashville, TN)

    Distance to nearest recruiting site
    <1 mi (city-level)
    Recruiting sites
    2 sites within 50 mi
  14. A Phase 1/1b Study of IAM1363 in HER2 Cancers

    NCT06253871

    • Phase 1
    • Ages 18 years and older
    • Sex: All

    Nearest sites: SCRI Oncology Partners (Nashville, TN); Vanderbilt Ingram Cancer Center (Nashville, TN)

    Distance to nearest recruiting site
    <1 mi (city-level)
    Recruiting sites
    2 sites within 50 mi
  15. A Study to Investigate the Safety and Efficacy of NST-628 Oral Tablets in Subjects With Solid Tumors

    NCT06326411

    • Phase 1
    • Ages 18 years and older
    • Sex: All

    Nearest sites: SCRI Oncology Partners (Nashville, TN); Vanderbilt-Ingram Cancer Center (Nashville, TN)

    Distance to nearest recruiting site
    <1 mi (city-level)
    Recruiting sites
    2 sites within 50 mi
  16. SMP-3124LP in Adults With Advanced Solid Tumors

    NCT06526819

    • Phase 1/2
    • Ages 18 years and older
    • Sex: All

    Nearest sites: SCRI Oncology Partners (Nashville, TN); Vanderbilt-Ingram Cancer Center (Nashville, TN)

    Distance to nearest recruiting site
    <1 mi (city-level)
    Recruiting sites
    2 sites within 50 mi
  17. A Study of Amivantamab in Combination With Lazertinib, or Amivantamab in Combination With Platinum-Based Chemotherapy, for Common Epidermal Growth Factor Receptor (EGFR)-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)

    NCT06667076

    • Phase 2
    • Ages 18 years and older
    • Sex: All

    Nearest sites: SCRI Oncology Partners (Nashville, TN); Tennessee Oncology (Nashville, TN)

    Distance to nearest recruiting site
    <1 mi (city-level)
    Recruiting sites
    2 sites within 50 mi
  18. Clinical Trial of N-803 Plus Tislelizumab or Prior Failed Immune Checkpoint Inhibitor and Docetaxel Versus Docetaxel Monotherapy in Participants With Advanced or Metastatic Non-Small Cell Lung Cancer Who Have Acquired Resistance to Immune Checkpoint In

    NCT06745908

    • Phase 3
    • Ages 18 to 90 years
    • Sex: All

    Nearest sites: Tennessee Oncology (Nashville, TN); Vanderbilt - Ingram Cancer Center (Nashville, TN)

    Distance to nearest recruiting site
    <1 mi (city-level)
    Recruiting sites
    2 sites within 50 mi
  19. Clinical Study of Ivonescimab for First-line Treatment of Metastatic NSCLC Patients With High PD-L1

    NCT06767514

    • Phase 3
    • Ages 18 years and older
    • Sex: All

    Nearest sites: Clinical Study Site (Nashville, TN); Clinical Study Sites (Nashville, TN)

    Distance to nearest recruiting site
    <1 mi (city-level)
    Recruiting sites
    2 sites within 50 mi
  20. A Study of CLSP-1025 in Adult Patients With Solid Tumors That Harbor the p53 R175H Mutation

    NCT06778863

    • Phase 1
    • Ages 18 years and older
    • Sex: All

    Nearest sites: Sarah Cannon Research Institute (SCRI) Oncology Partners (Nashville, TN); Vanderbilt University Medical Center (Nashville, TN)

    Distance to nearest recruiting site
    <1 mi (city-level)
    Recruiting sites
    2 sites within 50 mi
  21. Phase 1 Study of OP-3136 in Advanced or Metastatic Solid Tumors

    NCT06784193

    • Phase 1
    • Ages 18 years and older
    • Sex: All

    Nearest sites: SCRI Oncology Partners (Nashville, TN); Tennessee Oncology (Nashville, TN)

    Distance to nearest recruiting site
    <1 mi (city-level)
    Recruiting sites
    2 sites within 50 mi
  22. A Study to Learn About the Study Medicine Called PF-08046876 in People With Advanced Solid Tumors

    NCT07090499

    • Phase 1
    • Ages 18 years and older
    • Sex: All

    Nearest sites: SCRI Oncology Partners (Nashville, TN); Sarah Cannon Research Institute - Pharmacy (Nashville, TN)

    Distance to nearest recruiting site
    <1 mi (city-level)
    Recruiting sites
    2 sites within 50 mi
  23. Study to Assess the Efficacy and Safety of Rina-S in Participants With Non-small Cell Lung Cancer

    NCT07288177

    • Phase 2
    • Ages 18 years and older
    • Sex: All

    Nearest sites: Tennessee Oncology - Nashville St. Thomas Midtown Clinic (Nashville, TN); Tennessee Oncology Nashville - SCRI Oncology Partners (Nashville, TN)

    Distance to nearest recruiting site
    <1 mi (city-level)
    Recruiting sites
    2 sites within 50 mi
  24. A Study to Evaluate Pumitamig Versus Durvalumab Following Concurrent Chemoradiation Therapy in Participants With Unresectable Stage III Non-small Cell Lung Cancer (NSCLC) (ROSETTA Lung-201)

    NCT07361497

    • Phase 3
    • Ages 18 years and older
    • Sex: All

    Nearest sites: SCRI Oncology Partners (Nashville, TN); Tennessee Oncology (Nashville, TN)

    Distance to nearest recruiting site
    <1 mi (city-level)
    Recruiting sites
    2 sites within 50 mi
  25. A Study to Evaluate Adverse Events and Change in Disease Activity of Intravenous ABBV-706 Versus Standard of Care in Adult Participants With Relapsed/Refractory Small Cell Lung Cancer

    NCT07365241

    • Phase 3
    • Ages 18 years and older
    • Sex: All

    Nearest sites: SCRI Oncology Partners /ID# 279779 (Nashville, TN); Vanderbilt University Medical Center /ID# 280169 (Nashville, TN)

    Distance to nearest recruiting site
    <1 mi (city-level)
    Recruiting sites
    2 sites within 50 mi
  26. Phase 1 Study of PF-08046033 in Advanced Solid Tumors

    NCT07519655

    • Phase 1
    • Ages 18 years and older
    • Sex: All

    Nearest sites: SCRI Oncology Partners (Nashville, TN); Sarah Cannon Research Institute- Pharmacy (Nashville, TN)

    Distance to nearest recruiting site
    <1 mi (city-level)
    Recruiting sites
    2 sites within 50 mi
  27. Collecting and Analyzing Tissue Samples From Patients Undergoing Surgery for Non-Small Cell Lung Cancer

    NCT00897117

    • Observational
    • Ages 18 to 120 years
    • Sex: All

    Nearest site: Vanderbilt-Ingram Cancer Center (Nashville, TN)

    Distance to nearest recruiting site
    <1 mi (city-level)
    Recruiting sites
    1 site within 50 mi
  28. SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry

    NCT03452774

    • Observational
    • Ages Any age
    • Sex: All

    Nearest site: Massive Bio SYNERGY-AI site (Nashville, TN)

    Distance to nearest recruiting site
    <1 mi (city-level)
    Recruiting sites
    1 site within 50 mi
  29. A Study of Sigvotatug Vedotin in Advanced Solid Tumors

    NCT04389632

    • Phase 1
    • Ages 18 years and older
    • Sex: All

    Nearest site: US Oncology Research LLC (Nashville, TN)

    Distance to nearest recruiting site
    <1 mi (city-level)
    Recruiting sites
    1 site within 50 mi
  30. Osimertinib Alone or With Chemotherapy for EGFR-Mutant Lung Cancers

    NCT04410796

    • Phase 2
    • Ages 18 years and older
    • Sex: All

    Nearest site: Sarah Cannon Research Institute (Nashville, TN)

    Distance to nearest recruiting site
    <1 mi (city-level)
    Recruiting sites
    1 site within 50 mi
  31. The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)

    NCT04585750

    • Phase 1/2
    • Ages 12 years and older
    • Sex: All

    Nearest site: Sarah Cannon Research Institute (Nashville, TN)

    Distance to nearest recruiting site
    <1 mi (city-level)
    Recruiting sites
    1 site within 50 mi
  32. Study of PF-07248144 in Advanced or Metastatic Solid Tumors

    NCT04606446

    • Phase 2
    • Ages 18 years and older
    • Sex: All

    Nearest site: SCRI Oncology Partners (Nashville, TN)

    Distance to nearest recruiting site
    <1 mi (city-level)
    Recruiting sites
    1 site within 50 mi
  33. Phase 2 Trial of Adagrasib Monotherapy and in Combination With Pembrolizumab and a Phase 3 Trial of Adagrasib in Combination in Patients With a KRAS G12C Mutation KRYSTAL-7

    NCT04613596

    • Phase 2/3
    • Ages 18 years and older
    • Sex: All

    Nearest site: Tennessee Oncology - Nashville - Centennial Clinic - Medical Oncology (Nashville, TN)

    Distance to nearest recruiting site
    <1 mi (city-level)
    Recruiting sites
    1 site within 50 mi
  34. A Trial of RSC-1255 for Treatment of Patients With Advanced Malignancies

    NCT04678648

    • Phase 1
    • Ages 18 years and older
    • Sex: All

    Nearest site: Sarah Cannon, SCRI Oncology Partners (Nashville, TN)

    Distance to nearest recruiting site
    <1 mi (city-level)
    Recruiting sites
    1 site within 50 mi
  35. A Study of BMS-986340 as Monotherapy and as Combination Therapy in Participants With Advanced Solid Tumors

    NCT04895709

    • Phase 1/2
    • Ages 18 years and older
    • Sex: All

    Nearest site: Vanderbilt University Medical Center (Nashville, TN)

    Distance to nearest recruiting site
    <1 mi (city-level)
    Recruiting sites
    1 site within 50 mi
  36. A Study to Evaluate KIN-2787 in Participants With BRAF and/or NRAS Mutation Positive Solid Tumors

    NCT04913285

    • Phase 1
    • Ages 18 years and older
    • Sex: All

    Nearest site: Sarah Cannon Research Institute-Tennessee Oncology (Nashville, TN)

    Distance to nearest recruiting site
    <1 mi (city-level)
    Recruiting sites
    1 site within 50 mi
  37. Solid Tumor Analysis for HLA Loss of Heterozygosity (LOH) and Apheresis for CAR T- Cell Manufacturing

    NCT04981119

    • Observational
    • Ages 18 years and older
    • Sex: All

    Nearest site: Vanderbilt University Medical Center (Nashville, TN)

    Distance to nearest recruiting site
    <1 mi (city-level)
    Recruiting sites
    1 site within 50 mi
  38. First in Human Study of BAY2927088 in Participants Who Have Advanced Non-small Cell Lung Cancer (NSCLC) With Mutations in the Genes of Epidermal Growth Factor Receptor (EGFR) and/or Human Epidermal Growth Factor Receptor 2 (HER2)

    NCT05099172

    • Phase 1/2
    • Ages 18 years and older
    • Sex: All

    Nearest site: Tennessee Oncology - Nashville Centennial Clinic (Nashville, TN)

    Distance to nearest recruiting site
    <1 mi (city-level)
    Recruiting sites
    1 site within 50 mi
  39. Study of Zanzalintinib in Combination With Immuno-Oncology or Other Agents in Participants With Solid Tumors

    NCT05176483

    • Phase 1
    • Ages 18 years and older
    • Sex: All

    Nearest site: Exelixis Clinical Site #3 (Nashville, TN)

    Distance to nearest recruiting site
    <1 mi (city-level)
    Recruiting sites
    1 site within 50 mi
  40. Phase 1 Study of MRTX1719 in Solid Tumors With MTAP Deletion

    NCT05245500

    • Phase 1
    • Ages 18 years and older
    • Sex: All

    Nearest site: Vanderbilt - Ingram Cancer Center (Nashville, TN)

    Distance to nearest recruiting site
    <1 mi (city-level)
    Recruiting sites
    1 site within 50 mi
  41. Study of AU-007, A Monoclonal Antibody That Binds to IL-2 and Inhibits IL-2Rα Binding, in Patients With Unresectable Locally Advanced or Metastatic Cancer

    NCT05267626

    • Phase 1/2
    • Ages 18 years and older
    • Sex: All

    Nearest site: Sarah Cannon Research Institute (Nashville, TN)

    Distance to nearest recruiting site
    <1 mi (city-level)
    Recruiting sites
    1 site within 50 mi
  42. cfDNA Assay Prospective Observational Validation for Early Cancer Detection and Minimal Residual Disease

    NCT05366881

    • Observational
    • Ages 40 years and older
    • Sex: All
    • Accepts healthy volunteers

    Nearest site: Vanderbilt-Ingram Cancer Center (Nashville, TN)

    Distance to nearest recruiting site
    <1 mi (city-level)
    Recruiting sites
    1 site within 50 mi
  43. Study of RMC-6236 in Patients With Advanced Solid Tumors Harboring Specific Mutations in RAS

    NCT05379985

    • Phase 1/2
    • Ages 18 years and older
    • Sex: All

    Nearest site: Sarah Cannon Research Institute (Nashville, TN)

    Distance to nearest recruiting site
    <1 mi (city-level)
    Recruiting sites
    1 site within 50 mi
  44. Dose Escalation/Expansion Study of Mavrostobart (PT199), an Anti-CD73 mAb, Administered Alone and in Combination With a PD-1 Inhibitor or Chemotherapy (the MORNINGSTAR Study)

    NCT05431270

    • Phase 1/2
    • Ages 18 years and older
    • Sex: All

    Nearest site: SCRI Oncology Partners (Nashville, TN)

    Distance to nearest recruiting site
    <1 mi (city-level)
    Recruiting sites
    1 site within 50 mi
  45. Study of XmAb®819 in Subjects With Advanced Clear Cell Renal Cell Carcinoma

    NCT05433142

    • Phase 1
    • Ages 18 years and older
    • Sex: All

    Nearest site: Xencor Investigative Site (Nashville, TN)

    Distance to nearest recruiting site
    <1 mi (city-level)
    Recruiting sites
    1 site within 50 mi
  46. Split Course Adaptive Radiation Therapy With Pembrolizumab With/Without Chemotherapy for Treating Stage IV Lung Cancer

    NCT05501665

    • Phase 1/2
    • Ages 18 years and older
    • Sex: All

    Nearest site: Vanderbilt University/Ingram Cancer Center (Nashville, TN)

    Distance to nearest recruiting site
    <1 mi (city-level)
    Recruiting sites
    1 site within 50 mi
  47. A Study of a Selective T Cell Receptor (TCR) Targeting, Bifunctional Antibody-fusion Molecule STAR0602 in Participants With Advanced Solid Tumors

    NCT05592626

    • Phase 1/2
    • Ages 18 years and older
    • Sex: All

    Nearest site: Sarah Cannon Research Institute Oncology Partners (SCRI-Nashville) (Nashville, TN)

    Distance to nearest recruiting site
    <1 mi (city-level)
    Recruiting sites
    1 site within 50 mi
  48. A Study of DB-1310 in Advanced/Metastatic Solid Tumors

    NCT05785741

    • Phase 1/2
    • Ages 18 years and older
    • Sex: All

    Nearest site: Tennessee Oncology, PLLC (Nashville, TN)

    Distance to nearest recruiting site
    <1 mi (city-level)
    Recruiting sites
    1 site within 50 mi
  49. Phase 1/2 Trial of S241656 in Selected RAS/MAPK Mutation- Positive Malignancies

    NCT05786924

    • Phase 1/2
    • Ages 18 years and older
    • Sex: All

    Nearest site: Sarah Canon Research Institute (SCRI) Oncology Partners (Nashville, TN)

    Distance to nearest recruiting site
    <1 mi (city-level)
    Recruiting sites
    1 site within 50 mi
  50. A Study of NT-175 in Adult Participants With Advanced Malignancies That Are Positive for HLA-A*02:01 and the TP53 R175H Mutation

    NCT05877599

    • Phase 1
    • Ages 18 years and older
    • Sex: All

    Nearest site: Research Site (Nashville, TN)

    Distance to nearest recruiting site
    <1 mi (city-level)
    Recruiting sites
    1 site within 50 mi

FAQ

Common questions

What is a clinical trial?
A clinical trial is a research study in people that tests a medical, surgical or behavioral intervention, such as an investigational drug or device. Observational studies are also listed: they collect information without assigning a treatment. Read how clinical trials work.
Is there compensation for joining a Lung Cancer clinical trial?
Compensation for time and travel may be available, but it varies by study and some studies offer none. The amount and schedule are reviewed by an ethics board and described in the consent form. See compensation in clinical trials.
How do I check if I'm eligible?
Each study lists age, sex and other inclusion and exclusion criteria on its ClinicalTrials.gov record. Only the study team can confirm eligibility, usually through a screening call or visit. Talk with your own doctor before joining any study.

Source: ClinicalTrials.gov, data processed . Recruiting US sites filtered by distance and site status; summaries shortened.